CEL-SCI Corporation, a Phase 3 cancer immunotherapy company, is pleased to announce the pricing of its public offering of 794,117 shares of common stock at a price of $1.70 per share. The closing of the offering is anticipated for May 2, 2023, subject to customary closing conditions. Furthermore, the Company has granted the underwriter a 30-day option to purchase up to an additional 15 percent of the shares to cover any potential over-allotments.
Spartan Capital Securities, LLC, is proud to be exclusively leading the offering as sole book-running manager. With their expertise and guidance, the offering is sure to be a success!
The Company is thrilled to announce its offering of up to $1.35 million in gross proceeds, with the net proceeds to be used towards the continued development of Multikine*, LEAPS, and for general corporate purposes. Don’t miss out on this exciting opportunity to join us in this venture, as the funds from this offering will help us achieve even greater success.
About CEL-SCI Corporation
CEL-SCI is a pioneering biotechnology company on a mission to unlock the immune system’s potential in fighting cancer and infectious diseases. Their leading investigational therapy, Multikine, has achieved a pivotal Phase 3 clinical trial for head and neck cancer and has been granted Orphan Drug Designation by the FDA. With offices in Vienna, Virginia and near Baltimore, Maryland, CEL-SCI is working tirelessly to develop groundbreaking treatments for those in need.